Virtus Investment Advisers’s SpringWorks Therapeutics SWTX Stock Holding History

Virtus Investment Advisers’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,279	Closed	-$409K	–	491
2025 Q1	$409K	Buy	+9,279	New	+$427K	0.11%	207
2023 Q1	–	Sell	-2,752	Closed	-$71.6K	–	338
2022 Q4	$71.6K	Hold	2,752	–	–	0.05%	291
2022 Q3	$79K	Buy	+2,752	New	+$78.9K	0.04%	318

Other funds holding SWTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Virtus Investment Advisers's SWTX Position: Q2 2025 in Review

Virtus Investment Advisers sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 9,279 shares — an estimated $409K sold.

Virtus Investment Advisers first reported a position in SWTX in Q3 2022 and held it in 3 quarters. The position peaked at $409K in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Virtus Investment Advisers reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Virtus Investment Advisers sold 9,279 SpringWorks Therapeutics shares in Q2 2025, an estimated $409K.
Virtus Investment Advisers first reported a position in SpringWorks Therapeutics in Q3 2022 and held it in 3 quarters.
Virtus Investment Advisers's SpringWorks Therapeutics position peaked at $409K in Q1 2025.
223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Virtus Investment Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.